Back to: Psychedelics, Entheogens, and Consciousness Expansion
Module 1: The Essential Questions with Honest Answers
Essential Question 1
The MDMA program completed Phase 3 trials with response rates most psychiatric treatments would be thrilled to report, and the FDA rejected it anyway. What does that sequence tell you about the relationship between clinical evidence and institutional approval, and what should it teach you about how to read the next headline claiming a treatment has “failed” or “succeeded”?
Expanded Answer
Here’s my honest answer, offered as a starting point for your own, not a substitute for it. Clinical evidence and institutional approval are answering two different questions, and it’s a mistake most readers make constantly to assume they’re the same question asked twice. A Phase 3 trial answers, roughly, does this treatment outperform placebo in this specific population under these specific conditions. Regulatory approval answers a broader and messier question: can this specific trial’s design be trusted enough, and can this treatment be safely and consistently delivered outside the tightly controlled trial environment, to justify releasing it into the world. The MDMA trials answered the first question about as well as a psychiatric trial can. The advisory committee’s nine to two vote said the second question hadn’t been adequately answered, specifically around blinding integrity, adverse event reporting, and one documented case of therapist misconduct.
What this should teach you, practically, is to read past the headline verb. “Failed” and “succeeded” are doing enormous, often misleading work in a single word. When you see either one attached to a psychiatric or medical trial, the useful next question isn’t whether to believe it. It’s which specific claim failed or succeeded: the underlying biological effect, the trial’s methodology, or the regulatory judgment about readiness for real world deployment. Those are three separate things, and confusing any two of them is how false cynicism and false confidence both get manufactured. I’d add one more thing, watching this story continue to unfold into 2026: the same molecule class that got rejected in August 2024 is now, through a differently designed compound, sitting inside an accelerated FDA review process less than two years later. That whiplash isn’t evidence the system is broken or captured. It’s evidence the system is, at its best, slow, self-correcting, and stubbornly literal about methodology, even when the underlying medicine looks promising. Learn to expect that rhythm, and headlines in either direction will stop being able to rattle you.
Essential Question 2
If the intensity of a mystical type experience predicts the size of a clinical benefit, what does that suggest about what these substances are actually doing? Are they primarily correcting a chemical imbalance, or are they occasioning something closer to a genuine change in how a person understands their own existence, and does psychiatry’s own data force it to take that second possibility seriously, whether it’s comfortable with the implications?
Expanded Answer
I’ll give you my honest read, and I want to be clear it’s a read, not a settled fact. The data makes the pure chemical imbalance story hard to sustain as a complete explanation. If psilocybin worked purely as a biochemical correction, the way, say, insulin corrects a measurable deficiency, you’d expect symptom improvement to track dose and receptor occupancy most directly. Instead, across trial after trial, the single strongest predictor researchers keep finding isn’t dose alone. It’s the participant’s own subjective rating of how unitive, sacred, and ineffable the experience felt to them. That’s a strange thing for a strictly materialist model of mind to explain cleanly, because it puts the meaning of the experience, not merely its chemistry, in the explanatory driver’s seat.
I don’t think this proves anything metaphysical on its own, and I want to resist the temptation to claim it does. What I think it does, honestly, is force psychiatry to take seriously a category of explanation it has historically been reluctant to touch: that a genuine, felt reorganization of how a person understands their own existence, their mortality, their relationships, their sense of what’s sacred, may itself be the active therapeutic ingredient, with the neurochemistry serving as the door rather than the destination. That’s not a small concession for a field built on a strictly biomedical model to be backed into by its own randomized controlled trials. Whether you want to go further than that, toward something like the filter theory we’ll take up directly in Module 3, is a genuinely open question, and I’d rather you sit with your own answer honestly than borrow mine.
Essential Question 3
The psychedelic research of the 1950s and 1960s was mainstream, well-funded, and taken seriously by major institutions, right up until it wasn’t. What made that body of legitimate science vulnerable to being politically and culturally overturned in less than a decade, and what would it take to make sure the current renaissance doesn’t suffer the same fate?
Expanded Answer
My honest read: the 1960s research collapsed not because the science was weak, but because the science had no protective container around it. The findings were real, but they were entangled, in the public’s mind and eventually in the law, with uncontrolled recreational use, countercultural politics, and a handful of charismatic advocates, Leary chief among them, who blurred the line between careful researcher and public evangelist. When the political backlash against the counterculture arrived, it didn’t distinguish between a controlled Hopkins style trial and a college dorm room. It swept up both, because the public narrative had never bothered to draw that line clearly in the first place.
What would it take to avoid the same fate this time. I think the honest answer, looking at how this current wave has been built, is exactly the thing that makes it look so unglamorous and slow: institutional patience, methodological rigor that can survive hostile scrutiny, and a scrupulous refusal to let advocacy get ahead of the data. The MDMA rejection in 2024 is, in a strange way, evidence the system is working the way it should this time. A single trial site’s misconduct and a blinding problem got caught and acted on by an advisory committee, rather than buried until it became a scandal a decade later. That’s a slower, more frustrating process than a straight line to approval, and it’s also precisely the kind of process built to survive the next political mood swing rather than collapse under it. If this renaissance holds where the last one didn’t, it won’t be because the drugs are more forgiving. It will be because the people building it learned, the hard way, what happens when a scientific case gets ahead of its own institutional guardrails.